Oral Fluvoxamine Plus Inhaled Budesonide Reduced Prolonged ER Stays or Hospitalization for Acute COVID-19

Underpowered Multicenter Trial Confirms Expected Signal of Benefit Especially in Vaccinated Patients

By Peter A. McCullough, MD, MPH

As the COVID-19 pandemic winds down more clinical trials will report their results given the normal delays in human research and publication. Multicenter clinical trials are welcomed since they add to the supportive medical literature for multidrug intervention in higher risk patients with acute COVID-19. Since the COVID-19 vaccines have failed, the vaccinated group is of interest to trialists as they present with acute SARS-CoV-2 infection. A recent high quality multicenter trial testing fluvoxamine with inhaled budesonide was conducted during the Omicron era in Brazil.